• News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • Subscribe newsletter
  • Search
  • Menu Menu
International Hospital
  • AI
  • Cardiology
  • Oncology
  • Neurology
  • Genetics
  • Orthopaedics
  • Research
  • Surgery
  • Innovation
  • Medical Imaging
  • MedTech
  • Obs-Gyn
  • Paediatrics

Archive for category: Diagnostic tests

tool for NASH diagnosis

AI tool for NASH diagnosis receives first EMA qualification

AIM NASH, 11 April 2025/in Diagnostic tests, E-News, Product News /by panglobal

The European Medicines Agency has qualified the first artificial intelligence-based tool designed to evaluate liver biopsies in patients with metabolic dysfunction-associated steatohepatitis (MASH). The system, called AIM-NASH, helps pathologists assess disease severity and reduce variability in histological scoring, with the aim of accelerating drug development for this increasingly common liver condition.

Read more
https://interhospi.com/wp-content/uploads/sites/3/2025/04/liver.jpeg 518 922 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2025-04-11 08:00:212025-04-07 15:41:55AI tool for NASH diagnosis receives first EMA qualification
Billy Boyle, co-founder and CEO at Owlstone Medical

Cystic Fibrosis Foundation invests in Owlstone to develop breath test for Pseudomonas detection

, 8 April 2025/in Diagnostic tests, E-News /by panglobal

The Cystic Fibrosis Foundation has committed up to US$2.3 million (about £1.7 million) in equity investment to Owlstone Medical for the development of a breath test to detect Pseudomonas aeruginosa (PA) infections in people with cystic fibrosis (CF). The Cambridge-based company announced the investment on March 25, 2025, marking a significant step forward in respiratory […]

Read more
https://interhospi.com/wp-content/uploads/sites/3/2025/03/Billy-and-ReCIVA.jpg 667 1000 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2025-04-08 08:00:422025-03-31 13:21:42Cystic Fibrosis Foundation invests in Owlstone to develop breath test for Pseudomonas detection
Simple blood test measures type 1 diabetes autoimmunity in children

Simple blood test measures type 1 diabetes autoimmunity in children

, 2 April 2025/in Diabetes, Diagnostic tests, E-News /by panglobal

Researchers have developed a simple, robust blood test that accurately measures type 1 diabetes-related autoimmunity using minimal blood volumes, making it particularly suitable for paediatric patients. Called BASTA (β cell antigen-specific T cell assay), this test captures CD4+ T cell responses to pancreatic beta cells, offering an improved method to track autoimmune responses in both […]

Read more
https://interhospi.com/wp-content/uploads/sites/3/2025/03/T1-diabetes.jpeg 664 995 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2025-04-02 08:00:352025-03-31 12:46:07Simple blood test measures type 1 diabetes autoimmunity in children
Billy Boyle, Owlstone Medical CEO and co-founder

Breath diagnostics firm Owlstone secures £22m funding boost

, 6 February 2025/in Diagnostic tests, E-News /by panglobal

Diagnostic technology company Owlstone Medical has raised $27 million (£22m) in Series E financing to advance its breath-based testing platform for early disease detection, with particular focus on lung cancer, liver disease, and digestive disorders.  

Read more
https://interhospi.com/wp-content/uploads/sites/3/2025/02/Owlstone-Billy-Boyle-holds-ReCIVA.jpg 1080 1620 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2025-02-06 08:00:312025-02-02 07:05:27Breath diagnostics firm Owlstone secures £22m funding boost

New blood test promises rapid and accurate diagnosis of ALS

ALS, biomarker, blood test, diagnosis, microRNA, Research, 18 September 2024/in Diagnostic tests, E-News, Neurology /by panglobal

Researchers have developed a highly accurate blood test for amyotrophic lateral sclerosis (ALS), potentially reducing diagnosis times and improving patient outcomes.  

Read more
https://interhospi.com/wp-content/uploads/sites/3/2024/09/ALS.jpg 922 1382 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2024-09-18 08:00:172024-09-12 11:39:35New blood test promises rapid and accurate diagnosis of ALS

Latest issue of International Hospital

April 2024

28 May 2025

Breakthrough in vivo gene therapy targets newborn blood stem cells

28 May 2025

Major study exposes social media’s toxic impact on child mental health

27 May 2025

Ransomware emerges as primary driver of healthcare data breaches

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The medical devices information portal connecting healthcare professionals to global vendors

Sign in for our newsletter
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Media kit
    • Submit Press Release

Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com

PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Sign in for our newsletter

Free subscription